(PEN) Penumbra - Ratings and Ratios
Clot Removal, Vascular Access, Coil Devices, Surgical Tools
PEN EPS (Earnings per Share)
PEN Revenue
Description: PEN Penumbra
Penumbra Inc. is a medical device company that designs, develops, and markets innovative products for various medical applications, including peripheral thrombectomy, access, neuro embolization, peripheral embolization, and neurosurgical tools. The companys product portfolio includes the Indigo System, Lightning Flash, and Penumbra System, among others, which are used to treat conditions such as aneurysms, thrombus, and neurovascular lesions.
From a business perspective, Penumbra Inc. has a diverse revenue stream through its direct sales organizations and distributors, operating in the United States and internationally. The companys incorporation in 2004 and headquarters in Alameda, California, suggest a well-established presence in the healthcare industry. Key Performance Indicators (KPIs) such as revenue growth, gross margin, and research and development (R&D) expenditure as a percentage of revenue could provide further insights into the companys operational efficiency and innovation capabilities.
Analyzing the companys financials, a market capitalization of $9.16 billion and a forward P/E ratio of 67.11 indicate a significant market presence and expectations for future growth. The return on equity (RoE) of 3.65% suggests that the company may be facing challenges in generating returns for its shareholders. To improve this metric, Penumbra Inc. could focus on optimizing its product mix, enhancing operational efficiency, and investing in high-growth areas.
In terms of stock performance, the current price is $233.39, with support and resistance levels indicating potential price movements. To make informed investment decisions, it is essential to monitor the companys progress in developing new products, expanding its global reach, and managing its financials effectively. Key metrics to track include revenue growth, earnings per share (EPS), and cash flow generation, which can provide insights into the companys ability to drive long-term value creation.
PEN Stock Overview
| Market Cap in USD | 11,196m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2015-09-18 |
PEN Stock Ratings
| Growth Rating | 37.7% |
| Fundamental | 75.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 10.3% |
| Analyst Rating | 4.44 of 5 |
PEN Dividends
Currently no dividends paidPEN Growth Ratios
| Growth Correlation 3m | 58.3% |
| Growth Correlation 12m | 44.5% |
| Growth Correlation 5y | 1.2% |
| CAGR 5y | 11.60% |
| CAGR/Max DD 3y | 0.22 |
| CAGR/Mean DD 3y | 0.46 |
| Sharpe Ratio 12m | -0.50 |
| Alpha | 0.07 |
| Beta | 0.588 |
| Volatility | 40.33% |
| Current Volume | 418.2k |
| Average Volume 20d | 440.1k |
| Stop Loss | 249.1 (-3.4%) |
| Signal | 0.49 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (147.7m TTM) > 0 and > 6% of Revenue (6% = 76.8m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 2.44pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 70.91% (prev 69.93%; Δ 0.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 201.5m > Net Income 147.7m (YES >=105%, WARN >=100%) |
| Net Debt (-201.2m) to EBITDA (193.7m) ratio: -1.04 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (39.2m) change vs 12m ago 1.17% (target <= -2.0% for YES) |
| Gross Margin 66.47% (prev 62.51%; Δ 3.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 79.78% (prev 73.88%; Δ 5.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 132.9 (EBITDA TTM 193.7m / Interest Expense TTM 1.31m) >= 6 (WARN >= 3) |
Altman Z'' 4.98
| (A) 0.54 = (Total Current Assets 1.07b - Total Current Liabilities 157.8m) / Total Assets 1.67b |
| (B) 0.09 = Retained Earnings (Balance) 144.5m / Total Assets 1.67b |
| (C) 0.11 = EBIT TTM 174.6m / Avg Total Assets 1.60b |
| (D) 0.39 = Book Value of Equity 147.7m / Total Liabilities 380.9m |
| Total Rating: 4.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.11
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 1.49% = 0.75 |
| 3. FCF Margin 12.63% = 3.16 |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda 0.19 = 2.47 |
| 6. ROIC - WACC (= 1.69)% = 2.12 |
| 7. RoE 12.41% = 1.03 |
| 8. Rev. Trend 97.72% = 7.33 |
| 9. EPS Trend 75.18% = 3.76 |
What is the price of PEN shares?
Over the past week, the price has changed by -6.75%, over one month by +0.94%, over three months by +0.29% and over the past year by +31.79%.
Is Penumbra a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PEN is around 237.27 USD . This means that PEN is currently overvalued and has a potential downside of -7.95%.
Is PEN a buy, sell or hold?
- Strong Buy: 12
- Buy: 2
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 303.3 | 17.7% |
| Analysts Target Price | 303.3 | 17.7% |
| ValueRay Target Price | 263.9 | 2.4% |
Last update: 2025-09-11 04:46
PEN Fundamental Data Overview
CCE Cash And Equivalents = 421.8m USD (last quarter)
P/E Trailing = 75.7493
P/E Forward = 57.4713
P/S = 8.746
P/B = 8.6528
P/EG = 0.6792
Beta = 0.45
Revenue TTM = 1.28b USD
EBIT TTM = 174.6m USD
EBITDA TTM = 193.7m USD
Long Term Debt = 21.8m USD (from longTermDebtTotal, last quarter)
Short Term Debt = 15.3m USD (from shortTermDebt, last quarter)
Debt = 37.0m USD (Calculated: Short Term 15.3m + Long Term 21.8m)
Net Debt = -201.2m USD (from netDebt column, last quarter)
Enterprise Value = 10.81b USD (11.20b + Debt 37.0m - CCE 421.8m)
Interest Coverage Ratio = 132.9 (Ebit TTM 174.6m / Interest Expense TTM 1.31m)
FCF Yield = 1.49% (FCF TTM 161.6m / Enterprise Value 10.81b)
FCF Margin = 12.63% (FCF TTM 161.6m / Revenue TTM 1.28b)
Net Margin = 11.54% (Net Income TTM 147.7m / Revenue TTM 1.28b)
Gross Margin = 66.47% ((Revenue TTM 1.28b - Cost of Revenue TTM 429.2m) / Revenue TTM)
Tobins Q-Ratio = 73.20 (Enterprise Value 10.81b / Book Value Of Equity 147.7m)
Interest Expense / Debt = 0.86% (Interest Expense 319.0k / Debt 37.0m)
Taxrate = 32.86% (6.86m / 20.9m)
NOPAT = 117.2m (EBIT 174.6m * (1 - 32.86%))
Current Ratio = 6.75 (Total Current Assets 1.07b / Total Current Liabilities 157.8m)
Debt / Equity = 0.03 (Debt 37.0m / last Quarter total Stockholder Equity 1.29b)
Debt / EBITDA = 0.19 (Net Debt -201.2m / EBITDA 193.7m)
Debt / FCF = 0.23 (Debt 37.0m / FCF TTM 161.6m)
Total Stockholder Equity = 1.19b (last 4 quarters mean)
RoA = 8.82% (Net Income 147.7m, Total Assets 1.67b )
RoE = 12.41% (Net Income TTM 147.7m / Total Stockholder Equity 1.19b)
RoCE = 14.40% (Ebit 174.6m / (Equity 1.19b + L.T.Debt 21.8m))
RoIC = 9.85% (NOPAT 117.2m / Invested Capital 1.19b)
WACC = 8.15% (E(11.20b)/V(11.23b) * Re(8.18%)) + (D(37.0m)/V(11.23b) * Rd(0.86%) * (1-Tc(0.33)))
Shares Correlation 3-Years: 36.36 | Cagr: 0.31%
Discount Rate = 8.18% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 81.00% ; FCFE base≈141.2m ; Y1≈174.2m ; Y5≈297.3m
Fair Price DCF = 126.3 (DCF Value 4.93b / Shares Outstanding 39.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 75.18 | EPS CAGR: 405.2% | SUE: 0.47 | # QB: 0
Revenue Correlation: 97.72 | Revenue CAGR: 18.33% | SUE: 3.29 | # QB: 2
Additional Sources for PEN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle